Matamec Receives $15,445,022 CDN from TRECan for Kipawa HREE Deposit Definitive Feasibility Study

Matamec Explorations Inc. ("Matamec" or the "Company") is pleased to announce that the Company has received $1,100,558 CDN from its Japanese partner Toyotsu Rare Earth Canada Inc. ("Toyota" or "TRECan"), a subsidiary of Toyota Tsusho Corp. ("TTC"). The goal of the Kipawa mine project is to supply Toyota with heavy rare earths ("HREE") for the production and marketing of hybrid and electric vehicles.

To date Matamec has received $15,445,022 CDN of the maximum $16M CDN for the completion of a definitive feasibility study on the Kipawa HREE deposit, which is on budget and track for completion by the end of the second quarter of 2013.

"Matamec's team of professionals continue to deliver solid results as over 80% of the Kipawa feasibility study is near completion," said Andre Gauthier, President and CEO of Matamec Explorations. "We are most pleased to have Toyotsu as our strategic partner as their support positions Matamec favourably to take a key leadership position in becoming a leading global heavy rare earth company."

Under the terms of the Joint Venture Agreement ("JVA") by which TRECan can acquire 49% undivided interest in the Kipawa HREE Deposit, Matamec received $8.5M CDN for the first 25% undivided interest on July 18, 2012. To acquire the second 24% undivided interest, TRECan has to pay to Matamec a maximum amount of $7.5M CDN. The $1,100,558 CDN is the seventh of a number of successive payments in the completion of the $7.5M CDN, but the eighth overall payment received from TRECan. Matamec will transfer the 24% undivided interest to TRECan when it will receive a cumulative maximum amount of $7.5M CDN.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.